| Title | [Antidepressants in migraine prophylaxis] | | Author(s) | Nagata E | | Institution | Department of Neurology, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, Kanagawa 259-1193, Japan. | | Source | Brain Nerve 2009 Oct; 61(10):1131-4. | | Abstract | The initiation of a prophylactic treatment for migraine depends on the frequency of migraine attacks and the extent of the function disability associated with these attacks. Antidepressants have good evidence of efficacy in the prophylactic treatment for migraine. In general, among the antidepressants, amitriptyline is the most frequently prescribed by headache specialists. Several clinical trials on this drug have also evidenced the remarkable benefits of amitriptyline in the prophylactic treatment of migraine attack. In evidence-based guidelines developed by Japanese Headache Society and American Neurological Association, it is classified as a Group 1 drugs (effective drug for the prevention of migraine attack). Moreover, these drugs are more useful in cases where there is comorbidity with conditions such as depression. The side-effects of these drugs are sleepiness and dry mouth. Administration of amytriptyline at low dose can reduce the frequency of side effects such as sleepiness. | | Language | jpn | | Pub Type(s) | English Abstract
Journal Article
| | PubMed ID | 19882939 |
|
